Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 3/20 | 0.41 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2071594 | 0.81 | ULK1 (0.47) | ULK1ROCK2ROCK1SYKCDC7 | |
| SCHEMBL2071141 | 0.80 | ULK1 (0.44) | ULK1ROCK2ROCK1SYKCDC7 | |
| SCHEMBL12430952 | 0.76 | IGF1R (0.67) | ULK1IGF1R | |
| SCHEMBL5069231 | 0.75 | CDC7 (0.42) | ULK1SYKCDC7IGF1R | |
| SCHEMBL4455888 | 0.72 | HCAR2 (0.43) | IGF1R | |
| SCHEMBL31471788 | 0.71 | ULK1 (0.93) | ULK1ROCK2IGF1R | |
| SCHEMBL12430690 | 0.71 | ULK1 (0.93) | ULK1ROCK2IGF1R | |
| SCHEMBL12846046 | 0.71 | ULK1 (0.61) | ULK1IGF1R | |
| SCHEMBL1164159 | 0.71 | NEK1 (0.68) | ULK1CDC7IGF1R | |
| SCHEMBL2070672 | 0.71 | IGF1R (0.68) | ULK1ROCK1IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4160395-B2 | — | — | 2008-10-01 | — | — | JP | claimed |
| EP-1345927-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-17 | — | — | EP | claimed |
| US-20040214814-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2004-10-28 | — | — | US | claimed |
| JP-2004518703-A | — | — | 2004-06-24 | — | — | JP | claimed |
| EP-1345927-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-09-24 | — | — | EP | claimed |
| WO-2002062789-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-08-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214814-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | ULK1 683/4885ROCK2 27/4885ROCK1 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.